Lipoprotein(a) reduction with PCSK9-targeting pharmacotherapy: A prospective real-world registry study. (PubMed, Atherosclerosis) - Sep 30, 2026 - "In this large real-world cohort, PCSK9i therapies produced modest but significant reductions in lipoprotein(a). No statistically significant differences between agents were detected, although estimates for inclisiran were less precise because of the smaller sample size. Reductions were smaller than in randomised clinical trials, highlighting the need for targeted therapies."
Journal • Real-world evidence • Atherosclerosis • Cardiovascular
|
|
Anamarija Kelenc; Barbara Krevel; Borut Jug; Jan Kafol; Katarina Vrbinc; Klarisa Kepic; Lenart Kafol; Marko Novakovic; Matija Cevc; Miha Svarc; Urh Groselj; Zlatko Fras
|